

Table of Contents

2	Highlights
4	To Our Stakeholders ~Message from the Senior Management~
10	Management Topics 1 The Restructuring of U.S. Operations 2 Strengthening Strategy in Oncology Area
16	Corporate Philosophy
17	Corporate Governance
20	Intellectual Property
22	Special Feature Business Development in Europe R&D in Europe Operations in Europe Marketing in Europe CSR in Europe
	Corporate Activities and Performance in Fiscal 2007 Contribution to Society through Pharmaceutical Business
29	Takeda at a Glance / Industry Trends
30	Research and Development
32	R&D Pipeline
37	Production System
38	International Strategic Products (Ethical Drugs) / Consumer Healthcare Business
40	Marketing
	Relationship with Our Stakeholders
47	Relationship with Society
54	Relationship with Environment Special Feature: Global Warming Prevention
64	Relationship with Suppliers
66	Relationship with Employees
70	Financial Section
102	Independent Auditors' Report
103	Board of Directors, Auditors and Corporate Officers
104	Major Subsidiaries and Affiliates
106	Corporate Information

Editorial Policy

Takeda has issued an integrated Annual and CSR Report since fiscal 2006, in order to facilitate a comprehensive understanding of Takeda's activities by providing both financial and non-financial information, such as information on corporate social responsibility (CSR) activities. When preparing this integrated report, we have prioritized the inclusion of key items in relation to our financial and social responsibilities that should be conveyed to stakeholders. It is Takeda's sincere hope that this report allows our stakeholders to further understand Takeda's corporate activities.

This report covers a total of 65 Takeda group companies, consisting of Takeda Pharmaceutical Company Limited, and its 47 consolidated subsidiaries and 17 equity method affiliates. As for the disclosure of non-financial information, we have referred to the "Sustainability Reporting Guidelines*1" issued by the Global Reporting Initiative (GRI) and AA 1000*2.

*1 Sustainability Reporting Guidelines:
Guidelines issued by the Global Reporting Initiative that specify a globally applicable framework for sustainability reports.

*2 AA 1000:
Guidelines issued by British firm, AccountAbility that specify a systematic process in which stakeholders are involved in the course of developing communication systems, etc.

Regarding the Front Cover

Through its meaning "progress", the Japanese calligraphy of 進歩 progress shown on the front cover symbolizes Takeda's aim of making the progress to becoming a "World-Class Pharmaceutical Company." The calligraphy piece was composed by Japanese calligrapher, Mr. Souun Takeda, who has been offering his pieces of work since fiscal 2006.

Precautions Regarding Forward-Looking Statements

This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainties, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on.

* The contents of the annual report are written based on the information as of fiscal 2007 (April 1, 2007 to March 31, 2008) with some activities of significant relevance in fiscal 2008 being included.